Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study |
| Type de publication | Journal Article |
| Year of Publication | 2019 |
| Auteurs | Pouillon L, Lamoureux A, de Chambrun GPineton, Vuitton L, Pariente B, Zallot C, Dufour G, Fumery M, Baumann C, Amiot A, Nancey S, Rousseau H, Peyrin-Biroulet L |
| Journal | DIGESTIVE AND LIVER DISEASE |
| Volume | 51 |
| Pagination | 236-241 |
| Date Published | FEB |
| Type of Article | Article |
| ISSN | 1590-8658 |
| Mots-clés | Adalimumab, Crohn's disease, De-escalation, Inflammatory bowel disease, Ulcerative Colitis |
| Résumé | {Background: Data about the outcomes after adalimumab dose de-escalation in inflammatory bowel disease (IBD) are scarce. Objectives: To assess the outcomes after adalimumab dose de-escalation, and to identify potential factors associated with failure. Methods: Retrospective, observational study including all IBD patients who had undergone adalimumab dose de-escalation to 40 mg every three weeks across seven GETAID centers, between June 2011 and September 2017. Failure of adalimumab dose de-escalation was defined as the need for treatment re escalation, discontinuation of adalimumab, or clinical, biochemical and/or morphologic disease relapse. Results: Fifty-six patients were identified (n = 46 Crohn's disease |
| DOI | 10.1016/j.dld.2018.10.022 |